NIMGenetics, Spain’s leading biotech company in the field of human genetic diagnosis sector, continues its expansion in Europe with the acquisition of the Swiss company Gene Predictis, a leader in the field of Gene Predictis, a reference in the field of preventive health and precision medicine.
This acquisition reinforces NIMGenetics’ commitment to international expansion, with the focus on the Central European markets. The synergies of the two portfolios, as well as the growth of both companies’ customer base, willl place NIMGenetics at the forefront of the genetic diagnostics market in Europe.
NIMGenetics co-founder and CEO, Enrique Samper, has defended the potential of this transaction: “this acquisition will boost our expansion in Europe and will
acquisition will boost our expansion in Europe and usher in a new phase of development marked by future strategic alliances.”
The location of Gene Predictis in the EPFL Innovation Park in Lausanne (Ecole Polytechnique Fédérale de Lausanne) positions the Spanish biotech in a context with a strong innovative component, within an environment centred component, within an environment focused on the biotech, pharmaceutical and food tech industries.
In this sense, the CEO of Gene Predictis, Goranka Tanackovic, describes the integration into the group as a great opportunity to “expand our activity internationally, and to focus on our main areas of expertise.”
Avest Abogados advised the buyer with a team led by Jaime Espejo, who is also secretary of the Board of the company. BDO, Pinsent Masons, BAT Law and Kellerhals-Carrard also advised on this deal.
